Pharmacokinetics of Acebutolol in Patients with All Grades of Renal Failure

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1980 May 1

PMID 7418713

Citations 15

Authors

A Roux

P Aubert

J GUEDON

B Flouvat

Affiliations

Soon will be listed here.

Citing Articles

Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis.

Yeh T, Tu K, Hung K, Chuang M, Chen J PLoS One. 2022; 17(12):e0279680.

PMID: 36584227 PMC: 9803304. DOI: 10.1371/journal.pone.0279680.

β-Blocker Use and Cardiovascular Outcomes in Hemodialysis: A Systematic Review.

Tella A, Vang W, Ikeri E, Taylor O, Zhang A, Mazanec M Kidney Med. 2022; 4(5):100460.

PMID: 35539430 PMC: 9079357. DOI: 10.1016/j.xkme.2022.100460.

Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Bouchard J, Shepherd G, Hoffman R, Gosselin S, Roberts D, Li Y Crit Care. 2021; 25(1):201.

PMID: 34112223 PMC: 8194226. DOI: 10.1186/s13054-021-03585-7.

β-Blocker dialyzability and mortality in older patients receiving hemodialysis.

Weir M, Dixon S, Fleet J, Roberts M, Hackam D, Oliver M J Am Soc Nephrol. 2014; 26(4):987-96.

PMID: 25359874 PMC: 4378109. DOI: 10.1681/ASN.2014040324.

Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.

Flouvat B, Roux A, Chau N, VIALLET M, Andre-Fouet X, WOEHRLE R Eur J Clin Pharmacol. 1981; 19(4):287-92.

PMID: 7286031 DOI: 10.1007/BF00562806.

References

Eastwood J, Curtis J, Smith R . Pharmacodynamics of practolol in chronic renal failure. Br Med J. 1973; 4(5888):320-2. PMC: 1587452. DOI: 10.1136/bmj.4.5888.320. View

Roux A, Flouvat B, Delaveau P . [Spectrofluorometric determination of a new beta-blocking agent, acebutolol in blood and urine]. Ann Biol Clin (Paris). 1975; 33(4):281-8. View

Kaye C, Kumana C, FRANKLIN D, Baker L . A study of practolol elimination in all grades of chronic renal failure. Int J Clin Pharmacol Biopharm. 1975; 12(1-2):83-8. View

Lowenthal D, Briggs W, Gibson T, Nelson H, CIRKSENA W . Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther. 1974; 16(5 Part 1):761-9. DOI: 10.1002/cpt1974165part1761. View

Decourt S, Roux A, Baglin A, Domart M, Aubert P, Flouvat B . [Study of the binding of beta blockers to plasma proteins. Therapeutic consequences]. Acquis Med Recent. 1977; :181-94. View

Winkle R, Meffin P, Ricks W, Harrison D . Acebutolol metabolite plasma concentration during chronic oral therapy. Br J Clin Pharmacol. 1977; 4(5):519-22. PMC: 1429145. DOI: 10.1111/j.1365-2125.1977.tb00779.x. View

Ehrnebo M, AGURELL S, BOREUS L, Gordon E, Lonroth U . Pentazocine binding to blood cells and plasma proteins. Clin Pharmacol Ther. 1974; 16(3):424-9. DOI: 10.1002/cpt1974163part1424. View

SHAND D, Nuckolls E, OATES J . Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970; 11(1):112-20. DOI: 10.1002/cpt1970111112. View

Oie S, Levy G . Relationship between renal function and elimination kinetics of pindolol in man. Eur J Clin Pharmacol. 1975; 9(2-3):115-6. DOI: 10.1007/BF00614006. View

10.

Roux A, Aubert P, GUEDON J, Flouvat B . [Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis]. Nouv Presse Med. 1975; 4(46 Suppl):3228-33. View

11.

Meffin P, Harapat S, Harrison D . Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition kinetics in man. Res Commun Chem Pathol Pharmacol. 1976; 15(1):31-51. View

12.

Thompson F, JOEKES A, FOULKES D . Pharmacodynamics of propranolol in renal failure. Br Med J. 1972; 2(5811):434-6. PMC: 1788019. DOI: 10.1136/bmj.2.5811.434. View

13.

Lucsko M, Chaignon M, GUEDON J . [Acebutolol in arterial hypertension. Hemodynamic effects and effects on plasma renin]. Nouv Presse Med. 1975; 4(1):21-2, 24-5, 26. View

14.

FAULKNER J, Stopher D, Walden R . Pharmacokinetic and pharmacological studies with tolamolol in man. Br J Clin Pharmacol. 1975; 2(5):423-8. PMC: 1402620. DOI: 10.1111/j.1365-2125.1975.tb00551.x. View

15.

SHAND D . Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs. 1974; 7(1):39-47. DOI: 10.2165/00003495-197407010-00003. View

16.

Lavene D, Weiss Y, Safar M, Loria Y, Agorus N, Georges D . Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function. J Clin Pharmacol. 1977; 17(8-9):501-8. DOI: 10.1002/j.1552-4604.1977.tb05643.x. View

17.

Bass O, Nolph K, MAHER J . Dialysance and clearance measurements during clinical dialysis-a plea for standardization. J Lab Clin Med. 1975; 86(3):378-85. View

18.

Ohnhaus E, Nuesch E, Meier J, Kalberer F . Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia. Eur J Clin Pharmacol. 1974; 7(1):25-9. DOI: 10.1007/BF00614386. View

19.

Kaye C, Dufton J . Preliminary observations on the elimination of acebutolol in severe chronic renal failure. Br J Clin Pharmacol. 1976; 3(1):198-9. PMC: 1428803. DOI: 10.1111/j.1365-2125.1976.tb00591.x. View

20.

Meffin P, Winkle R, Peters F, Harrison D . Dose-dependent acebutolol disposition after oral administration. Clin Pharmacol Ther. 1978; 24(5):542-7. DOI: 10.1002/cpt1978245542. View